Literature DB >> 19821096

Expression of matrix metalloproteinase and its tissue inhibitor in haemangioma.

Shan Zhong1, Guohua Yang, Cong Xia, Zhang Duanlian, Shengguo Shan.   

Abstract

The action mechanism of matrix metalloproteinases-2 (MMP-2) and tissue inhibitor of metalloproteinases-2 (TIMP-2) in the genesis, development and degeneration of haemangioma was investigated by detecting their expression in the tissue of haemangioma in different phases by using the immunohistochemistry. Fifty paraffin-embedded specimens of skin capillary haemangioma were collected, which were documented in the Department of Pathology, Renmin Hospital of Wuhan University from 2000 to 2006. All samples were stained by regular HE method, and proliferative cell nuclear antigen (PCNA) was tested by immunohistochemical S-P method. The samples were classified according to the Mulliken criteria and the expression pattern of PCNA. Immunohistochemical S-P method was applied to detect the expression of MMP-2 and TIMP-2 in proliferative and degenerative phases of cutaneous capillary haemangioma, and in normal skin tissues. In combination with the detection of the expression of factor VIII-related antigen, it was verified that in haemangioma tissues, the cells expressing MMP-2 and TIMP-2 were vascular endothelial cells. The MMP-2 and TIMP-2 expression was quantitatively analyzed by image analysis system (HPIAS-1000), and one-way ANOVA(107) and SNK(q) test were done to analyze average absorbance (A) and positive area rate of immunohistochemically positive particles by using SPSS11.5. The results showed: (1) Among 50 samples of haemangioma, there were 26 proliferative haemangiomas, and 24 degenerative haemangiomas, respectively; (2) The expression of MMP-2 was weak in normal vascular endothelial cells, cytoplasm of connective tissues and extracellular matrix around blood vessels. The expression of MMP-2 in proliferative group was significantly higher than in degenerative group and control group (normal skin) (P<0.05), but there was no statistically significant difference between the latter two groups; (3) TIMP-2 was highly expressed in normal tissues, degenerative vascular endothelial cells, cytoplasm of connective tissues and extracellular matrix around blood vessels. The expression level of TIMP-2 in proliferative phase was significantly lower than in degenerative phase (P<0.05), and the expression of TIMP-2 in proliferative phase was significantly different from that in degenerative phase and normal tissues (P<0.05). It was concluded that in proliferative phase of haemangioma, MMP-2 may promote over-proliferation of endothelial cells of haemangioma, and in degenerative phase, TIMP-2 can inhibit the proliferation of endothelial cells of haemangioma. The two substances play important roles in the genesis, development and degeneration of haemangiomas.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19821096     DOI: 10.1007/s11596-009-0516-3

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  24 in total

Review 1.  Recent progress in our understanding of the pathogenesis of infantile hemangiomas.

Authors:  Sheila Fallon Friedlander; Matthew R Ritter; Martin Friedlander
Journal:  Lymphat Res Biol       Date:  2005       Impact factor: 2.589

Review 2.  Hemangiomas: an overview.

Authors:  Michael J Sundine; Garrett A Wirth
Journal:  Clin Pediatr (Phila)       Date:  2007-04       Impact factor: 1.168

3.  Increased expression of matrix metalloproteinase-9 in the eutopic endometrial tissue of women with endometriosis.

Authors:  T Collette; R Maheux; J Mailloux; A Akoum
Journal:  Hum Reprod       Date:  2006-07-31       Impact factor: 6.918

Review 4.  Beneficial and detrimental influences of tissue inhibitor of metalloproteinase-1 (TIMP-1) in tumor progression.

Authors:  William Hornebeck; Elise Lambert; Emmanuelle Petitfrère; Philippe Bernard
Journal:  Biochimie       Date:  2005 Mar-Apr       Impact factor: 4.079

5.  Genomic imprinting of IGF2 is maintained in infantile hemangioma despite its high level of expression.

Authors:  Ying Yu; Jill Wylie-Sears; Elisa Boscolo; John B Mulliken; Joyce Bischoff
Journal:  Mol Med       Date:  2004 Jul-Dec       Impact factor: 6.354

6.  Role of melatonin in regulating matrix metalloproteinase-9 via tissue inhibitors of metalloproteinase-1 during protection against endometriosis.

Authors:  Sumit Paul; Anamika Vivek Sharma; Pramathes Das Mahapatra; Partha Bhattacharya; Russel J Reiter; Snehasikta Swarnakar
Journal:  J Pineal Res       Date:  2008-02-19       Impact factor: 13.007

7.  Matrix metalloproteinases 2 and 9, E-cadherin, and beta-catenin expression in endometriosis, low-grade endometrial carcinoma and non-neoplastic eutopic endometrium.

Authors:  Ruthy Shaco-Levy; Shalom Sharabi; Daniel Benharroch; Benjamin Piura; Netta Sion-Vardy
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2008-03-04       Impact factor: 2.435

Review 8.  The pathogenesis of hemangiomas: a review.

Authors:  Constantijn G Bauland; Maurice A M van Steensel; Peter M Steijlen; Paul N M A Rieu; Paul H M Spauwen
Journal:  Plast Reconstr Surg       Date:  2006-02       Impact factor: 4.730

Review 9.  Pathogenesis of infantile haemangioma: new molecular and cellular insights.

Authors:  Matthew R Ritter; Ross A Butschek; Martin Friedlander; Sheila F Friedlander
Journal:  Expert Rev Mol Med       Date:  2007-11-29       Impact factor: 5.600

10.  Structural and functional uncoupling of the enzymatic and angiogenic inhibitory activities of tissue inhibitor of metalloproteinase-2 (TIMP-2): loop 6 is a novel angiogenesis inhibitor.

Authors:  Cecilia A Fernández; Catherine Butterfield; Geraldine Jackson; Marsha A Moses
Journal:  J Biol Chem       Date:  2003-08-04       Impact factor: 5.157

View more
  2 in total

1.  Urinary matrix metalloproteinases-2/9 in healthy infants and haemangioma patients prior to and during propranolol therapy.

Authors:  C J Kleber; A Spiess; J B Kleber; U Hinz; S Holland-Cunz; J Weiss
Journal:  Eur J Pediatr       Date:  2011-12-28       Impact factor: 3.183

2.  Role of connexins in infantile hemangiomas.

Authors:  Katja Blanke; Ingo Dähnert; Aida Salameh
Journal:  Front Pharmacol       Date:  2013-04-16       Impact factor: 5.810

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.